PM PM Philip Morris International Loading... : Bullish and Bearish Analyst Opinions

The tweet previews the upcoming earnings week with GOOGL and INTC in focus, noting AI spending scrutiny and semiconductor sector pressure after a bear market correction.

PM and MO NTM PE multiples cited as near the top of their recent historical ranges, flagged as a valuation risk within XLP.

FDA decision permits Zyn nicotine pouches to carry reduced-risk labeling; regulatory milestone for Philip Morris.

FDA authorization lets Zyn market reduced-risk claims, a positive regulatory development for PM, but the author does not disclose a position or explicit buy/hold call.

FDA authorizes Philip Morris to market Zyn nicotine pouches as less harmful than cigarettes, per CNBC report

Philip Morris International announces FDA authorization to market Zyn nicotine pouches as less harmful than cigarettes.

FDA allows Zyn to sell nicotine pouches citing health benefits according to an Axios report.

The tweet discusses regulatory tightening on e-cigarette imports and highlights Philip Morris's high gross margin and dividend yield, but presents it as a question rather than an explicit position or recommendation.

Philip Morris cuts its profit forecast for this fiscal year after writing down the value of its investment in its Canadian affiliate by $500 million.

Short PM on vape danger

Short PM on Zyn danger

Zyns dangerous, short PM

Barbarian Capital notes Philip Morris hitting a new intraday all-time high and questions whether the TAM expansion was already priced into models for PM, MO, and BTI.

Speaker notes PM's successful pivot from cigarettes to smokeless products (vapes, pouches), with 43% of revenue now from smokeless — framed as a business model strength, no explicit directional commitment.

Summarizes FDA guidance on vapes and pouches; no directional view from speaker.

Dr. Friedrich Franz tweets a WSJ report that Trump is pressuring the FDA to approve flavored vapes, which could benefit tobacco stocks MO and PM if approved.

A highly upvoted comment from a self-proclaimed physician advocates for the benefits of nicotine and buying Philip Morris calls. In a stressful macro environment, "vice" stocks like tobacco often show resilience and steady cash flows. Long PM calls as a defensive, consumer-staple play during market turbulence. Regulatory crackdowns on tobacco/nicotine products or general market beta dragging the stock down.

"By 2030, we should have a total of the revenues coming from this product [smoke-free]." Additionally, "IQOS today's revenue is larger than Marlboro" and Zyn shipments are predicted to hit 1 billion in 2026. PMI has successfully executed a "self-disruption" strategy. By acquiring Swedish Match (Zyn) and developing IQOS, they have immunized themselves against the secular decline of smoking. They are capturing a new demographic (white-collar workers) who would never smoke cigarettes but will use discreet pouches. The construction of the Colorado facility indicates massive demand and a move to secure US market share against competitors like Altria. Long PM as the clear winner in the "Nicotine 2.0" transition, offering growth (Zyn) and stability (legacy pricing power) with a valuation that may re-rate higher as it becomes less of a "sin stock" and more of a consumer packaged goods (CPG) play. Regulatory crackdown on flavored pouches (similar to vaping bans); long-term health studies revealing cardiovascular risks associated with high-concentration nicotine pouches.

Olczak states that 40% of Philip Morris International's revenue is now "smoke-free" (IQOS and Zyn). He projects Zyn shipments to more than double from 421 million cans in 2023 to over 1 billion in 2026. The market historically discounts tobacco for terminal decline in combustibles. However, PM is successfully transitioning to a growth multiple business (Oral Nicotine/Heat-not-Burn). If Zyn volumes double, revenue quality improves, warranting a re-rating from "value trap" to "growth staple." Long PM as the clear winner in the nicotine transition, specifically for its ownership of Zyn (US growth engine) and IQOS (International scale). Regulatory crackdowns on flavored pouches; potential long-term health studies linking pouches to cardiovascular issues.

Author is long PM to express a bullish view on modern oral nicotine pouches (e.g., Zyn) over traditional cigarettes.

Investors are fleeing asset-light businesses due to AI disruption fears. Brown identifies "HALO" stocks (Heavy Assets, Low Obsolescence) as the new leadership. An LLM cannot replicate a physical bag of Fritos (Pepsi), refine gasoline (Valero), or pour concrete (Martin Marietta). These companies have "moats of physics" that AI cannot cross. LONG. These sectors (Energy, Industrials, Staples) are seeing massive inflows as "refugees" from the SaaS crash seek safety in non-disruptible cash flows. Some names (like KO) are becoming technically overbought (RSI 85+), suggesting a short-term pullback is likely within a longer uptrend.

Buy Philip Morris based on an active internal BUY Signal reviewed pre-market; speaker's proprietary signal framework has triggered a bullish directional call.